Dr Brose is the director of the Thyroid Cancer Therapuetics Program and is a global leader in the development of the new field of thyroid cancer oncology. Her Phase II clinical trial of sorafenib in patients with advanced thyroid cancer lead to the successful completion of the first Phase III study, in this disease group (RAI refractory thyroid cancer). She was also one of the top accuers and lead site for the Phase III trial of cabozantinib for advance medullary thyroid cancer, which lead to FDA approval of this agent in November of 2012. Requested to speak and teach worldwide on her experience in the the use of novel agents to treat patients with all types of advanced thyroid cancer (Differentiate, Medullary, and Anaplastic), she is a global leader and educator to physicians and patients alike.
Dr. Brose also runs a lab in the field of translational studies in cancer genetics and genomics. Dr. Brose’s basic science research interest involves the identification of genetic abnormalities in the tumors of patients undergoing targeted therapies. Most of her research centers on translational projects directly related to samples obtained in the course of her clinical trial program. However, occasionally, science leads to leads in other tumor types. She currently has projects underway in thyroid cancer, breast cancer, lung cancer, colon cancer and esophageal cancer. Once identified, she is interested in understanding if these changes may identify tumors that may have or lack resistance to certain compounds. She has experience in the use of mice, drosophila, human tissue culture and clincal tissue samples. Her analytic tools include all types of PCR, RT-PCR, as well as the use of array comparative genomic hybridization (aCGH) and transcription profiling, taqman analysis, Q-RT-PCR and DNA sequencing on a regular basis, and whole and targeted genome sequencing. She also uses high resolution expression and SNP genotyping tetchnologies (Affymetrix and Illumina) to study the genetic basis of cancer. Dr. Brose provides the key correlative science for ongoing phaseI/II/III clinical trials at the University and internationally.
Cohen AB, Brose MS: Second-line treatment for advanced thyroid cancer: an indication in need of randomized clinical trials. J Clin Endocrinol Metab. 99 (6): 1995-7,2014.
Brose,M.S., Nutting,C.M., Jarzab, B., Elisei, R., Siena, S., Bastholt,L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, YK, Sherman, SI, Smit, JWA, Chung, J., Kappeler, C., Pena, C., Molnar, I., Schlumberger, M.J., on behalf of the DECISION Investigators*: Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase III trial The Lancet 14 : 60421-9,2014.
Brose,M.S., Frenette,C.T., Keefe, S.M., Stein, S.M.: Management of Sorafenib-Related Adverse Events:
A Clinician’s Perspective Seminars in Oncology 41 (1): S1-S16,2014.
Schlumberger, M., Brose, M., Elisei,R.,
Leboulleux, S., Luster, M., Pitoia, F., Pacini, F.: Definition and management of radioactive iodine-refractory
differentiated thyroid cancer (published online ahead of print) Lancet Diabetes and Endocrinology : 2014.
View all publications